FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
In this webinar, our panel of Africa-based researchers discuss the strong clinical research foundation, the community-centered approach and increasing regulatory harmonization in Africa. Watch to learn about the continent’s population diversity, expanding therapeutic area expertise and long-standing stakeholder engagement.
To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”
Lassa fever is a type of hemorrhagic fever caused by the Lassa virus and is mainly transmitted by rodents. The virus was first detected in 1969 in the town of Lassa, in Borno State, Nigeria; hence, its name. Lassa is endemic to West Africa, specifically Nigeria, Liberia, Sierra Leone and Guinea. A significant number of individuals infected by the Lassa virus (~80%) do not appear to develop symptoms. The case fatality rate (CFR) has been reported to be upwards of 70%
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA